p>In January 1997, 62 subjects who had drug been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement treatment in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From for the pms spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice drug daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, treatment the active for group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the pms placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication drug for the active group compared to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10

With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo treatment group (n=49) on the primary endpoint, defined for as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment pms in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent drug technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels treatment to one-year. For the seasonal for allergens reported, the active group (n=27) had on average pms a greater reduction in IgE than the drug and treatment and for placebo group (n=34) for 13 out of 16 allergens. pms.

©2003 www.female-prenatal-supplements.com All rights reserved.